2072 related articles for article (PubMed ID: 33740362)
1. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
2. Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations.
Argoff CE; Alford DP; Fudin J; Adler JA; Bair MJ; Dart RC; Gandolfi R; McCarberg BH; Stanos SP; Gudin JA; Polomano RC; Webster LR
Pain Med; 2018 Jan; 19(1):97-117. PubMed ID: 29206984
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
[TBL] [Abstract][Full Text] [Related]
4. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
5. Trends in prior receipt of prescription opioid or adjuvant analgesics among patients with incident opioid use disorder or opioid-related overdose from 2006 to 2016.
Wei YJ; Chen C; Schmidt SO; LoCiganic WH; Winterstein AG
Drug Alcohol Depend; 2019 Nov; 204():107600. PubMed ID: 31586806
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation and tapering of prescribed opioids and risk of overdose among people on long-term opioid therapy for pain with and without opioid use disorder in British Columbia, Canada: A retrospective cohort study.
Kennedy MC; Crabtree A; Nolan S; Mok WY; Cui Z; Chong M; Slaunwhite A; Ti L
PLoS Med; 2022 Dec; 19(12):e1004123. PubMed ID: 36454732
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Wang L; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
J Clin Psychol; 2023 Dec; 79(12):2869-2883. PubMed ID: 37584532
[TBL] [Abstract][Full Text] [Related]
9. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
10. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
11. Trends in prescription opioid use and dose trajectories before opioid use disorder or overdose in US adults from 2006 to 2016: A cross-sectional study.
Wei YJ; Chen C; Fillingim R; Schmidt SO; Winterstein AG
PLoS Med; 2019 Nov; 16(11):e1002941. PubMed ID: 31689302
[TBL] [Abstract][Full Text] [Related]
12. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
[TBL] [Abstract][Full Text] [Related]
13. Opioid tapering in patients with prescription opioid use disorder: A retrospective study.
Zhou K; Jia P; Bhargava S; Zhang Y; Reza T; Peng YB; Wang GG
Scand J Pain; 2017 Oct; 17():167-173. PubMed ID: 28988103
[TBL] [Abstract][Full Text] [Related]
14. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
[No Abstract] [Full Text] [Related]
15. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder.
Maricich YA; Xiong X; Gerwien R; Kuo A; Velez F; Imbert B; Boyer K; Luderer HF; Braun S; Williams K
Curr Med Res Opin; 2021 Feb; 37(2):175-183. PubMed ID: 33140981
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
17. Predictors of availability of long-acting medication for opioid use disorder.
Shover CL; Humphreys K
Drug Alcohol Depend; 2019 Nov; 204():107586. PubMed ID: 31593871
[TBL] [Abstract][Full Text] [Related]
18. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
[TBL] [Abstract][Full Text] [Related]
19. Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
Rogal S; Youk A; Agbalajobi O; Zhang H; Gellad W; Fine MJ; Belperio P; Morgan T; Good CB; Kraemer K
Am J Gastroenterol; 2021 Jul; 116(7):1406-1413. PubMed ID: 33811202
[TBL] [Abstract][Full Text] [Related]
20. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Grove LR; Rao N; Domino ME
Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]